Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Investment Perspective

Scancell has reported H119 results in line with expectations. The cash position was £7.6m, with the net loss of £3.24m compensated for by the two equity raises, totalling £14.9m, over the past year. Development appears to be progressing well, with important clinical programmes expected to start patient recruitment during the next two quarters. Additionally, in January 2019 the management team has been strengthened by two important new hires. As detailed in our Initiation note, we value the company, using a risk-adjusted DCF model, at £82.0m, or 21.1p a share.

Market information

SymbolPrimary exchangeCurrency
Last PriceMarket Cap
52 Week Low52 Week High


Vulpes investment brings £3.88m in new funds
Lighthouse | 13 Jun 2019
SCIB2 to use new nanoparticle formulation
Lighthouse | 20 May 2019
Phase II melanoma study with SCIB1 to start in Q219
Lighthouse | 25 Apr 2019

Recent News

Share subscription and issue of equity to Vulpes Life Sciences Fund
13 Jun 2019
Update on SC1B2 development
20 May 2019
Establishment of Clinical Advisory Board and update on Modi1 progress
10 May 2019
UK regulatory approval to start SCIB1 Phase II advanced melanoma trial
25 Apr 2019